Last updated: 2026-10-12 11:30:01. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
GRI Bio, Inc. (GRI) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.75, with a market capitalization of $3.80M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.36 to $64.12. This page covers its latest market performance, valuation, price trends and company information.
$3.80M | |
$1.76 | |
$2,248,100.40 | |
$1.36 | |
$1.74 | |
876.00 | |
333.28K | |
-- | |
$64.12 | |
$1.36 | |
-- | |
-- |
GRI Bio, Inc. (GRI) is trading at $1.75 in pre-market trading as of 2026-10-12 10:41:00, up 0.29% ($0.01) from the previous close of $1.74
Pre-market trading shows how investors are pricing GRI before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, GRI Bio, Inc. (GRI) moved from $1.96 to $1.75, representing a decline of 10.97% ($0.21).
The stock traded between $1.68 and $2.04 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 39.03 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.6%
GRI is currently trading at $1.75, placing it 0.6% of the way from its 52-week low of $1.36 to its 52-week high of $64.12. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 5 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of GRI Bio, Inc. (GRI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.